Unmet Need
Prostate cancer (PC) is the most common non-cutaneous malignancy in men with over 1.4 million new cases diagnosed globally in 2020 (see Wang 2022). Although disease confined to the prostate is highly curable, many men will be diagnosed with metastatic prostate cancer which is not curable but is treatable. The gold standard of care is androgen...
Value Proposition:
· Detection of methylation patterns that are linked to prostate cancer development in an individual.
· Enable development of a personalized treatment plan for individuals with aggressive prostate cancer.
· Simultaneous determination of gene methylation and copy number.
Technology Description
Researchers...
Value Proposition:
· Metastatic castration-resistant prostate cancer (mCRPC) treatment that offers reduced side effects due to its mechanism of action (MoA)
· HDAC4 inhibition prevents the upregulation of stress survival pathways, which in turn may prevent metastases in mCRPC
· Similar anti-cancer agents must be dosed at lower...
Unmet Need
According to the American Cancer Society, prostate cancer is one of the most commonly diagnosed cancers and is the second leading cause of cancer death in men. However, most patients with prostate cancer have the low-risk, nonaggressive form that does not require invasive intervention or treatment. The gold standard of diagnosing men with...
Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become...
Unmet Need
Prostate cancer is the second most common type of cancer in American men, behind skin cancer. It is also the second leading cause of cancer deaths in American males, and there is a continuing need for innovation in diagnosis for those at risk for prostate cancer.
After initial diagnostic blood tests for prostate-specific antigens, a prostate...
Unmet Need
Prostate cancer is considered the most common type of cancer in men with approximately 249,000 new cases and an estimated 34,130 deaths in 2021 (see ACS). Prostate cancer treatment is dependent on tumor staging with early stage intervention including surgery or radiotherapy and later stage management by androgen deprivation therapy (see...
There is a crucial need of discovering novel biomarkers in addition to prostate specific antigen (PSA) to improve the specificity of clinical diagnosis for prostate cancer. This invention addresses this problem by discovering proteins from prostate cancer tissues that can be detected in patients’ blood. Hence, a blood test can be developed for detecting...
Unmet Need / Invention Novelty: Men with prostate cancer develop resistance to androgen deprivation therapy (castration resistant prostate cancer) and must rely on less defined subsequent lines of therapy. Increasing resistance develops with each subsequent line of hormonal therapy. There exists an unmet clinical need to overcome resistance to hormone...
Unmet Need: Despite widespread research efforts, breast cancer remains the second leading cause of cancer deaths in women. There is an urgent need to identify novel biomarkers and treatment strategies against aggressive forms of breast cancer to improve prognosis and therapy.
Technical Details: Johns Hopkins researchers have identified a novel biomarker...
Unmet Need / Invention Novelty: Current prostate-specific antigen (PSA)-based tests lack specificity in differentiating between aggressive and non-aggressive prostate cancer (PC), the latter of which does not require invasive intervention or treatment. Aggressive prostate cancer is therefore over-diagnosed and overtreated. There is an unmet need to...
Unmet Need
Effective radiation treatment of tumors combines maximal radiation dose delivery to planned locations while mitigating radiation impacts on surrounding normal tissues. A delivery of radiation absorption materials (biocompatible gels) to create pockets of radiation dissipation has proven to be an effective method to mask unwanted effects....
UNMET NEED
The current standards of care for prostate cancer (Pca) include hormonal therapy, radiation therapy, surgery, chemotherapy, and combinational therapy. However, these treatments often have side effects that affect the quality of life of the Pca patients. Hence, there is an urgent need for developing better target-based therapies. This technology...
Unmet Need
Prostate cancer is the leading cancer in the U.S. population and the second leading cause of cancer death in men. A promising precision cancer treatment known as photodynamic therapy (PDT) offers a way to selectively target prostate cancer cells for destruction. Prostate PDT uses a ligand to attach a light-sensitizing agent known as porphyrin...
Unmet Need
According to The American Cancer Society, approximately 1 in 9 men will be diagnosed with prostate cancer in their lifetime, with 174,650 new cases diagnosed yearly in the US. As prostate cancer is the second leading cause of cancer death in American men, early detection is important for adequate treatment. The most common method of detecting...
Unmet Need
Prostate cancer is the most common non-cutaneous malignancy. Additionally, it is the second leading cause of cancer related deaths among men in the United States with nearly 1 in every 6 men predicted to be diagnosed with the disease at some point in their lives. Currently, the most common biopsy method is a transrectal ultrasound (TRUS)...
Unmet Need
Prostate cancer is the second leading cause of cancer related death in American men and it is estimated that approximately 164,690 new cases will be diagnosed in 2018. Elevated prostate-specific membrane antigen (PSMA) serves as a biomarker for prostate cancer and as well as primary clear cell renal carcinoma (ccRCC). However, PSMA is also...
Unmet Need
Prostate cancer is one of the most commonly diagnosed cancers in the male population; roughly one out of ten men will be diagnosed at some point in their lives. Efficient screening and accurate diagnosis is a public health imperative due to the large potential patient population. Prostate cancer is usually diagnosed following an abnormal...
Unmet Need
There is increasing evidence supporting that ‘loss of function’ of metastasis suppressor genes plays an important role in cancer metastases. To help identify metastasis suppressor genes on human chromosomes, Johns Hopkins researchers have transferred individual human chromosomes into metastatic rat prostate cancer cells.
Technology Overview
To...
Unmet Need
Prostate-specific membrane antigen (PSMA, also known as GCPII) is a validated target for prostate cancer imaging and therapy. Macromolecular reagents, most notably monoclonal antibodies (mAbs), offer a viable alternative to small-molecule PSMA ligands for imaging and therapy. However existing anti-PSMA antibodies have several drawbacks,...
